Heart drug improves exercise tolerance in clinical trial of patients with hypertrophic ...
Aficamten, a cardiac myosin inhibitor, improved exercise tolerance in patients with hypertrophic obstructive cardiomyopathy in the SEQUIOA-HCM trial, enhancing peak oxygen uptake and cardiac function, as published in JAMA Cardiology.
Related Clinical Trials
Reference News
Aficamten, a cardiac myosin inhibitor, improved exercise tolerance in patients with hypertrophic obstructive cardiomyopathy in the SEQUIOA-HCM trial, enhancing peak oxygen uptake and cardiac function, as published in JAMA Cardiology.
Aficamten improved exercise capacity by changing cardiac function in a study led by Mass General Brigham researchers, published in JAMA Cardiology.
Aficamten treatment improves exercise performance in obstructive HCM, significantly enhancing multiple exercise measures in a 24-week trial, with correlations to clinical responses.